메뉴 건너뛰기




Volumn 4, Issue 1, 2011, Pages 31-41

Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis

Author keywords

Antimicrobial treatment; Cystic fibrosis; Pseudomonas aeruginosa; Respiratory infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CIPROFLOXACIN; COLISTIN; DORIPENEM; IMIPENEM; IMMUNOGLOBULIN ANTIBODY; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PSEUDOMONAS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

EID: 79952646501     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S16263     Document Type: Article
Times cited : (53)

References (110)
  • 1
    • 0024453308 scopus 로고
    • Identification of the cystic fibrosis gene: Chromosome walking and jumping
    • Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059-1065.
    • (1989) Science , vol.245 , Issue.4922 , pp. 1059-1065
    • Rommens, J.M.1    Iannuzzi, M.C.2    Kerem, B.3
  • 2
    • 0027395872 scopus 로고
    • The changing epidemiology of cystic fibrosis
    • FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122(1):1-9.
    • (1993) J Pediatr , vol.122 , Issue.1 , pp. 1-9
    • Fitzsimmons, S.C.1
  • 3
    • 79952643169 scopus 로고    scopus 로고
    • Cystic Fibrosis Foundation Patient Registry, Bethesda, MD: Cystic Fibrosis Foundation 2009
    • Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2008. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
    • Annual Data Report 2008
  • 4
    • 0036320272 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    • Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.
    • (2002) Pediatr Pulmonol , vol.34 , Issue.2 , pp. 91-100
    • Emerson, J.1    Rosenfeld, M.2    McNamara, S.3    Ramsey, B.4    Gibson, R.L.5
  • 5
    • 0034764166 scopus 로고    scopus 로고
    • Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis
    • Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32(5):356-366.
    • (2001) Pediatr Pulmonol , vol.32 , Issue.5 , pp. 356-366
    • Rosenfeld, M.1    Gibson, R.L.2    McNamara, S.3
  • 6
    • 0142043977 scopus 로고    scopus 로고
    • Pathophysiology and management of pulmonary infections in cystic fibrosis
    • Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-951.
    • (2003) Am J Respir Crit Care Med , vol.168 , Issue.8 , pp. 918-951
    • Gibson, R.L.1    Burns, J.L.2    Ramsey, B.W.3
  • 7
    • 0029875463 scopus 로고    scopus 로고
    • Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward
    • Döring G, Jansen S, Noll H, et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol. 1996;21(2):90-100.
    • (1996) Pediatr Pulmonol , vol.21 , Issue.2 , pp. 90-100
    • Döring, G.1    Jansen, S.2    Noll, H.3
  • 8
    • 9644295892 scopus 로고    scopus 로고
    • National Nosocomial Infections Surveillance (NNIS) System Report, data summary from 1992 Jan through 2004 Jun, issued 2004 Oct
    • National Nosocomial Infections Surveillance System
    • National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from 1992 Jan through 2004 Jun, issued 2004 Oct. Am J Infect Control. 2004;32(8):470-485.
    • (2004) Am J Infect Control , vol.32 , Issue.8 , pp. 470-485
  • 9
    • 12844270608 scopus 로고    scopus 로고
    • Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis
    • Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293(5):581-588.
    • (2005) JAMA , vol.293 , Issue.5 , pp. 581-588
    • Li, Z.1    Kosorok, M.R.2    Farrell, P.M.3
  • 10
    • 0031873820 scopus 로고    scopus 로고
    • Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis
    • Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol. 1998;26(2):81-88.
    • (1998) Pediatr Pulmonol , vol.26 , Issue.2 , pp. 81-88
    • Kosorok, M.R.1    Jalaluddin, M.2    Farrell, P.M.3
  • 12
  • 13
    • 34248658815 scopus 로고    scopus 로고
    • Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection
    • Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2007;2:153-164.
    • (2007) Future Microbiol , vol.2 , pp. 153-164
    • Govan, J.R.1    Brown, A.R.2    Jones, A.M.3
  • 14
    • 33744814106 scopus 로고    scopus 로고
    • Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
    • Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A. 2006;103(22):8487-8492.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , Issue.22 , pp. 8487-8492
    • Smith, E.E.1    Buckley, D.G.2    Wu, Z.3
  • 15
    • 17144382063 scopus 로고    scopus 로고
    • Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis
    • Ramsey DM, Wozniak DJ. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol. 2005; 56(2):309-322.
    • (2005) Mol Microbiol , vol.56 , Issue.2 , pp. 309-322
    • Ramsey, D.M.1    Wozniak, D.J.2
  • 16
    • 0141650541 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection
    • Song Z, Wu H, Ciofu O, et al. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol. 2003;52(Pt 9):731-740.
    • (2003) J Med Microbiol , vol.52 , Issue.PART 9 , pp. 731-740
    • Song, Z.1    Wu, H.2    Ciofu, O.3
  • 17
    • 0029814366 scopus 로고    scopus 로고
    • Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia
    • Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996;60(3):539-574.
    • (1996) Microbiol Rev , vol.60 , Issue.3 , pp. 539-574
    • Govan, J.R.1    Deretic, V.2
  • 18
    • 0035353081 scopus 로고    scopus 로고
    • Multidrug efflux in Pseudomonas aeruginosa: Components, mechanisms and clinical significance
    • Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem. 2001;1(1):59-71.
    • (2001) Curr Top Med Chem , vol.1 , Issue.1 , pp. 59-71
    • Poole, K.1    Srikumar, R.2
  • 19
    • 0027494050 scopus 로고
    • Multiple antibiotic resistance in Pseudomonas aeruginosa: Evidence for involvement of an efflux operon
    • Poole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol. 1993;175(22):7363-7372.
    • (1993) J Bacteriol , vol.175 , Issue.22 , pp. 7363-7372
    • Poole, K.1    Krebes, K.2    McNally, C.3    Neshat, S.4
  • 20
    • 0042769424 scopus 로고    scopus 로고
    • Ambler class A extendedspectrum beta-lactamases in Pseudomonas aeruginosa: Novel developments and clinical impact
    • Weldhagen GF, Poirel L, Nordmann P. Ambler class A extendedspectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother. 2003;47(8):2385-2392.
    • (2003) Antimicrob Agents Chemother , vol.47 , Issue.8 , pp. 2385-2392
    • Weldhagen, G.F.1    Poirel, L.2    Nordmann, P.3
  • 21
    • 0018377101 scopus 로고
    • The chest roentgenogram in cystic fibrosis: A new scoring system
    • Brasfield D, Hicks G, Soong S, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics. 1979;63(1): 24-29.
    • (1979) Pediatrics , vol.63 , Issue.1 , pp. 24-29
    • Brasfield, D.1    Hicks, G.2    Soong, S.3    Tiller, R.E.4
  • 22
    • 0027535889 scopus 로고
    • Wisconsin cystic fibrosis chest radiograph scoring system
    • Weatherly MR, Palmer CG, Peters ME, et al. Wisconsin cystic fibrosis chest radiograph scoring system. Pediatrics. 1993;91(2): 488-495.
    • (1993) Pediatrics , vol.91 , Issue.2 , pp. 488-495
    • Weatherly, M.R.1    Palmer, C.G.2    Peters, M.E.3
  • 23
    • 0030790441 scopus 로고    scopus 로고
    • High- resolution CT in the acute exacerbation of cystic fibrosis: Evaluation of acute findings, reversibility of those findings, and clinical correlation
    • Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC. High- resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol. 1997;169(2):375-380.
    • (1997) AJR Am J Roentgenol , vol.169 , Issue.2 , pp. 375-380
    • Shah, R.M.1    Sexauer, W.2    Ostrum, B.J.3    Fiel, S.B.4    Friedman, A.C.5
  • 24
    • 0033006235 scopus 로고    scopus 로고
    • Evolution of CT findings in patients with cystic fibrosis
    • Helbich TH, Heinz-Peer G, Fleischmann D, et al. Evolution of CT findings in patients with cystic fibrosis. AJR Am J Roentgenol. 1999;173(1):81-88.
    • (1999) AJR Am J Roentgenol , vol.173 , Issue.1 , pp. 81-88
    • Helbich, T.H.1    Heinz-Peer, G.2    Fleischmann, D.3
  • 25
    • 0031949095 scopus 로고    scopus 로고
    • Cystic fibrosis: When should highresolution computed tomography of the chest be obtained?
    • Santamaria F, Grillo G, Guidi G, et al. Cystic fibrosis: when should highresolution computed tomography of the chest be obtained? Pediatrics. 1998;101(5):908-913.
    • (1998) Pediatrics , vol.101 , Issue.5 , pp. 908-913
    • Santamaria, F.1    Grillo, G.2    Guidi, G.3
  • 26
    • 0020585150 scopus 로고
    • Changes in the normal maximal expiratory flow-volume curve with growth and aging
    • Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127(6):725-734.
    • (1983) Am Rev Respir Dis , vol.127 , Issue.6 , pp. 725-734
    • Knudson, R.J.1    Lebowitz, M.D.2    Holberg, C.J.3    Burrows, B.4
  • 27
    • 0020525824 scopus 로고
    • Distribution of forced vital capacity and forced expiratory volume in one second in children 6 to 11 years of age
    • Dockery DW, Berkey CS, Ware JH, Speizer FE, Ferris BG Jr. Distribution of forced vital capacity and forced expiratory volume in one second in children 6 to 11 years of age. Am Rev Respir Dis. 1983;128(3):405-412.
    • (1983) Am Rev Respir Dis , vol.128 , Issue.3 , pp. 405-412
    • Dockery, D.W.1    Berkey, C.S.2    Ware, J.H.3    Speizer, F.E.4    Ferris Jr, B.G.5
  • 28
    • 0026520359 scopus 로고
    • Prediction of mortality in patients with cystic f ibrosis
    • Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic f ibrosis. N Engl J Med. 1992;326(18):1187-1191.
    • (1992) N Engl J Med , vol.326 , Issue.18 , pp. 1187-1191
    • Kerem, E.1    Reisman, J.2    Corey, M.3    Canny, G.J.4    Levison, H.5
  • 29
    • 0033531143 scopus 로고    scopus 로고
    • Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.Cystic Fibrosis Inhaled Tobramycin Study Group
    • Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30.
    • (1999) N Engl J Med , vol.340 , Issue.1 , pp. 23-30
    • Ramsey, B.W.1    Pepe, M.S.2    Quan, J.M.3
  • 30
    • 0032718969 scopus 로고    scopus 로고
    • Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis
    • Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999;28(5):321-328.
    • (1999) Pediatr Pulmonol , vol.28 , Issue.5 , pp. 321-328
    • Rosenfeld, M.1    Emerson, J.2    Accurso, F.3
  • 31
    • 0030001433 scopus 로고    scopus 로고
    • Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis
    • Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21(5):267-275.
    • (1996) Pediatr Pulmonol , vol.21 , Issue.5 , pp. 267-275
    • Armstrong, D.S.1    Grimwood, K.2    Carlin, J.B.3    Carzino, R.4    Olinsky, A.5    Phelan, P.D.6
  • 32
    • 0035060298 scopus 로고    scopus 로고
    • Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis
    • Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax. 2001;56(4):306-311.
    • (2001) Thorax , vol.56 , Issue.4 , pp. 306-311
    • Henig, N.R.1    Tonelli, M.R.2    Pier, M.V.3    Burns, J.L.4    Aitken, M.L.5
  • 33
    • 0042922372 scopus 로고    scopus 로고
    • Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis
    • Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol. 2003;41(9):4009-4015.
    • (2003) J Clin Microbiol , vol.41 , Issue.9 , pp. 4009-4015
    • Miller, M.B.1    Gilligan, P.H.2
  • 34
    • 23844474727 scopus 로고    scopus 로고
    • Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients
    • Cantón R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11(9): 690-703.
    • (2005) Clin Microbiol Infect , vol.11 , Issue.9 , pp. 690-703
    • Cantón, R.1    Cobos, N.2    de Gracia, J.3
  • 35
    • 0034016422 scopus 로고    scopus 로고
    • Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients
    • Burns JL, Saiman L, Whittier S, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 2000;38(5):1818-1822.
    • (2000) J Clin Microbiol , vol.38 , Issue.5 , pp. 1818-1822
    • Burns, J.L.1    Saiman, L.2    Whittier, S.3
  • 36
    • 0032804197 scopus 로고    scopus 로고
    • Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis
    • Saiman L, Burns JL, Whittier S, Krzewinski J, Marshall SA, Jones RN. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol. 1999;37(9):2987-2991.
    • (1999) J Clin Microbiol , vol.37 , Issue.9 , pp. 2987-2991
    • Saiman, L.1    Burns, J.L.2    Whittier, S.3    Krzewinski, J.4    Marshall, S.A.5    Jones, R.N.6
  • 37
    • 0034821607 scopus 로고    scopus 로고
    • Defining a pulmonary exacerbation in cystic fibrosis
    • Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001;139(3):359-365.
    • (2001) J Pediatr , vol.139 , Issue.3 , pp. 359-365
    • Rosenfeld, M.1    Emerson, J.2    Williams-Warren, J.3
  • 38
    • 0032433579 scopus 로고    scopus 로고
    • Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis.Current practice and suggestions for future directions
    • Touw DJ, Vinks AA, Mouton JW, Horrevorts AM. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin Pharmacokinet. 1998;35(6):437-459.
    • (1998) Clin Pharmacokinet , vol.35 , Issue.6 , pp. 437-459
    • Touw, D.J.1    Vinks, A.A.2    Mouton, J.W.3    Horrevorts, A.M.4
  • 39
    • 0023628218 scopus 로고
    • Antibiotic pharmacokinetics in cystic fibrosis.Differences and clinical significance
    • De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet. 1987;13(4):228-253.
    • (1987) Clin Pharmacokinet , vol.13 , Issue.4 , pp. 228-253
    • de Groot, R.1    Smith, A.L.2
  • 40
    • 70350593962 scopus 로고    scopus 로고
    • Update on antibiotics for infection control in cystic fibrosis
    • Kirkby S, Novak K, McCoy K. Update on antibiotics for infection control in cystic fibrosis. Expert Rev Anti Infect Ther. 2009;7(8):967-980.
    • (2009) Expert Rev Anti Infect Ther , vol.7 , Issue.8 , pp. 967-980
    • Kirkby, S.1    Novak, K.2    McCoy, K.3
  • 41
    • 0030664021 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis
    • Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest. 1997;112(5):1208-1213.
    • (1997) Chest , vol.112 , Issue.5 , pp. 1208-1213
    • Bates, R.D.1    Nahata, M.C.2    Jones, J.W.3
  • 42
    • 13844254908 scopus 로고    scopus 로고
    • Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: A randomised controlled trial
    • Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet. 2005;365(9459):573-578.
    • (2005) Lancet , vol.365 , Issue.9459 , pp. 573-578
    • Smyth, A.1    Tan, K.H.2    Hyman-Taylor, P.3
  • 43
    • 77950899558 scopus 로고    scopus 로고
    • Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
    • CD002009
    • Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2010;(1):CD002009.
    • (2010) Cochrane Database Syst Rev. , vol.1
    • Smyth, A.R.1    Bhatt, J.2
  • 44
    • 0142105983 scopus 로고    scopus 로고
    • Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management
    • Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med. 2003;9(6):492-497.
    • (2003) Curr Opin Pulm Med , vol.9 , Issue.6 , pp. 492-497
    • Rosenfeld, M.1    Ramsey, B.W.2    Gibson, R.L.3
  • 45
    • 0025868478 scopus 로고
    • Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
    • Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991;338(8769):725-726.
    • (1991) Lancet , vol.338 , Issue.8769 , pp. 725-726
    • Valerius, N.H.1    Koch, C.2    Høiby, N.3
  • 46
    • 0030995361 scopus 로고    scopus 로고
    • Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
    • Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23(5):330-335.
    • (1997) Pediatr Pulmonol , vol.23 , Issue.5 , pp. 330-335
    • Frederiksen, B.1    Koch, C.2    Høiby, N.3
  • 47
    • 77955413607 scopus 로고    scopus 로고
    • Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis
    • Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev. 2010;11(3):177-184.
    • (2010) Paediatr Respir Rev , vol.11 , Issue.3 , pp. 177-184
    • Stuart, B.1    Lin, J.H.2    Mogayzel Jr, P.J.3
  • 48
    • 77950126962 scopus 로고    scopus 로고
    • Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
    • CD004197
    • Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;(4):CD004197.
    • (2009) Cochrane Database Syst Rev , vol.4
    • Langton Hewer, S.C.1    Smyth, A.R.2
  • 49
    • 0037445216 scopus 로고    scopus 로고
    • Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
    • Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):841-849.
    • (2003) Am J Respir Crit Care Med , vol.167 , Issue.6 , pp. 841-849
    • Gibson, R.L.1    Emerson, J.2    McNamara, S.3
  • 50
    • 59649123905 scopus 로고    scopus 로고
    • Acquisition and eradication of P.aeruginosa in young children with cystic fibrosis
    • Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 2009;33(2):305-311.
    • (2009) Eur Respir J , vol.33 , Issue.2 , pp. 305-311
    • Douglas, T.A.1    Brennan, S.2    Gard, S.3
  • 51
    • 77957874451 scopus 로고    scopus 로고
    • Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: Is susceptibility testing justified?
    • Macdonald D, Cuthbertson L, Doherty C, et al. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J Antimicrob Chemother. 2010;65(11):2373-2375.
    • (2010) J Antimicrob Chemother , vol.65 , Issue.11 , pp. 2373-2375
    • Macdonald, D.1    Cuthbertson, L.2    Doherty, C.3
  • 52
    • 0036157901 scopus 로고    scopus 로고
    • Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
    • Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121(1):55-63.
    • (2002) Chest , vol.121 , Issue.1 , pp. 55-63
    • Moss, R.B.1
  • 53
    • 36248953255 scopus 로고    scopus 로고
    • Cystic f ibrosis pulmonary guidelines: Chronic medications for maintenance of lung health
    • Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic f ibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-969.
    • (2007) Am J Respir Crit Care Med , vol.176 , Issue.10 , pp. 957-969
    • Flume, P.A.1    O'Sullivan, B.P.2    Robinson, K.A.3
  • 54
    • 0036736583 scopus 로고    scopus 로고
    • A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
    • Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20(3):658-664.
    • (2002) Eur Respir J , vol.20 , Issue.3 , pp. 658-664
    • Hodson, M.E.1    Gallagher, C.G.2    Govan, J.R.3
  • 55
  • 56
    • 0034835277 scopus 로고    scopus 로고
    • Microbiological and immunologic considerations with aerosolized drug delivery
    • LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest. 2001;120(3 Suppl):118S-123S.
    • (2001) Chest , vol.120 , Issue.3 SUPPL. , pp. 118-123
    • Lipuma, J.J.1
  • 57
    • 0029958486 scopus 로고    scopus 로고
    • Pharmacokinetics of inhaled drugs
    • Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42(6):697-705.
    • (1996) Br J Clin Pharmacol , vol.42 , Issue.6 , pp. 697-705
    • Lipworth, B.J.1
  • 58
    • 4444256217 scopus 로고    scopus 로고
    • Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients
    • Badia JR, Soy D, Adrover M, et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother. 2004;54(2):508-514.
    • (2004) J Antimicrob Chemother , vol.54 , Issue.2 , pp. 508-514
    • Badia, J.R.1    Soy, D.2    Adrover, M.3
  • 59
    • 77953877127 scopus 로고    scopus 로고
    • Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis
    • Guy EL, Bosomworth M, Denton M, Conway SP, Brownlee KG, Lee TW. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis. J Cyst Fibros. 2010;9(4):292-295.
    • (2010) J Cyst Fibros , vol.9 , Issue.4 , pp. 292-295
    • Guy, E.L.1    Bosomworth, M.2    Denton, M.3    Conway, S.P.4    Brownlee, K.G.5    Lee, T.W.6
  • 60
    • 77951642713 scopus 로고    scopus 로고
    • Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia
    • Luyt CE, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13(6):R200.
    • (2009) Crit Care , vol.13 , Issue.6
    • Luyt, C.E.1    Clavel, M.2    Guntupalli, K.3
  • 61
    • 0347812929 scopus 로고    scopus 로고
    • Aerosolized antibiotics in cystic fibrosis
    • Sexauer WP, Fiel SB. Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med. 2003;24(6):717-726.
    • (2003) Semin Respir Crit Care Med , vol.24 , Issue.6 , pp. 717-726
    • Sexauer, W.P.1    Fiel, S.B.2
  • 63
    • 65949124667 scopus 로고    scopus 로고
    • Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
    • Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232.
    • (2009) Chest , vol.135 , Issue.5 , pp. 1223-1232
    • Retsch-Bogart, G.Z.1    Quittner, A.L.2    Gibson, R.L.3
  • 64
    • 78349232036 scopus 로고    scopus 로고
    • Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa
    • Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis. 2010;202(10):1585-1592.
    • (2010) J Infect Dis , vol.202 , Issue.10 , pp. 1585-1592
    • Herrmann, G.1    Yang, L.2    Wu, H.3
  • 65
    • 0024267448 scopus 로고
    • Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis
    • Reed MD, Stern RC, Myers CM, Yamashita TS, Blumer JL. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol. 1988;28(8):691-699.
    • (1988) J Clin Pharmacol , vol.28 , Issue.8 , pp. 691-699
    • Reed, M.D.1    Stern, R.C.2    Myers, C.M.3    Yamashita, T.S.4    Blumer, J.L.5
  • 66
    • 0025633092 scopus 로고
    • Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: Clinical significance and therapeutic approaches
    • Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother. 1990;26 Suppl F: 165-179.
    • (1990) J Antimicrob Chemother , vol.26 , Issue.SUPPL. F , pp. 165-179
    • Ball, P.1
  • 67
    • 0141816759 scopus 로고    scopus 로고
    • Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial
    • Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756.
    • (2003) JAMA , vol.290 , Issue.13 , pp. 1749-1756
    • Saiman, L.1    Marshall, B.C.2    Mayer-Hamblett, N.3
  • 68
    • 0036188534 scopus 로고    scopus 로고
    • Macrolide antibiotics and cystic fibrosis
    • Peckham DG. Macrolide antibiotics and cystic fibrosis. Thorax. 2002;57(3):189-190.
    • (2002) Thorax , vol.57 , Issue.3 , pp. 189-190
    • Peckham, D.G.1
  • 69
    • 33750078400 scopus 로고    scopus 로고
    • Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells
    • Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006;350(4):977-982.
    • (2006) Biochem Biophys Res Commun , vol.350 , Issue.4 , pp. 977-982
    • Cigana, C.1    Nicolis, E.2    Pasetto, M.3    Assael, B.M.4    Melotti, P.5
  • 70
    • 33751177801 scopus 로고    scopus 로고
    • Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice
    • Legssyer R, Huaux F, Lebacq J, et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res. 2006;7:134.
    • (2006) Respir Res , vol.7 , pp. 134
    • Legssyer, R.1    Huaux, F.2    Lebacq, J.3
  • 72
    • 8644251326 scopus 로고    scopus 로고
    • Azithromycin for cystic fibrosis
    • Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J. 2004;24(5):834-838.
    • (2004) Eur Respir J , vol.24 , Issue.5 , pp. 834-838
    • Southern, K.W.1    Barker, P.M.2
  • 73
    • 0037190575 scopus 로고    scopus 로고
    • Long term azithromycin in children with cystic fibrosis: A randomised, placebo- controlled crossover trial
    • Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo- controlled crossover trial. Lancet. 2002;360(9338):978-984.
    • (2002) Lancet , vol.360 , Issue.9338 , pp. 978-984
    • Equi, A.1    Balfour-Lynn, I.M.2    Bush, A.3    Rosenthal, M.4
  • 74
    • 0025230752 scopus 로고
    • Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
    • Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141(4 Pt 1): 914-921.
    • (1990) Am Rev Respir Dis , vol.141 , Issue.4 PART 1 , pp. 914-921
    • Regelmann, W.E.1    Elliott, G.R.2    Warwick, W.J.3    Clawson, C.C.4
  • 75
    • 0029934215 scopus 로고    scopus 로고
    • Management of pulmonary disease in patients with cystic fibrosis
    • Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996;335(3):179-188.
    • (1996) N Engl J Med , vol.335 , Issue.3 , pp. 179-188
    • Ramsey, B.W.1
  • 76
    • 0033498208 scopus 로고    scopus 로고
    • Comparison of a beta- lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis
    • Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta- lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr. 1999;134(4):413-421.
    • (1999) J Pediatr , vol.134 , Issue.4 , pp. 413-421
    • Smith, A.L.1    Doershuk, C.2    Goldmann, D.3
  • 77
    • 70350446684 scopus 로고    scopus 로고
    • Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations
    • Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.
    • (2009) Am J Respir Crit Care Med , vol.180 , Issue.9 , pp. 802-808
    • Flume, P.A.1    Mogayzel Jr, P.J.2    Robinson, K.A.3
  • 79
    • 21844443142 scopus 로고    scopus 로고
    • Single versus combination intravenous antibiotic therapy for people with cystic fibrosis
    • CD002007
    • Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2005;2:CD002007.
    • (2005) Cochrane Database Syst Rev , vol.2
    • Elphick, H.E.1    Tan, A.2
  • 80
    • 44949111525 scopus 로고    scopus 로고
    • Duration of intravenous antibiotic therapy in people with cystic fibrosis
    • CD006682
    • Fernandes B, Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2008;2:CD006682.
    • (2008) Cochrane Database Syst Rev , vol.2
    • Fernandes, B.1    Plummer, A.2    Wildman, M.3
  • 81
    • 0030935245 scopus 로고    scopus 로고
    • Home intravenous therapy in cystic fibrosis: A prospective randomized trial examining clinical, quality of life and cost aspects
    • Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J. 1997;10(4):896-900.
    • (1997) Eur Respir J , vol.10 , Issue.4 , pp. 896-900
    • Wolter, J.M.1    Bowler, S.D.2    Nolan, P.J.3    McCormack, J.G.4
  • 83
    • 0029198302 scopus 로고
    • Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: A cross-over randomized study
    • Braggion C, Cappelletti LM, Cornacchia M, Zanolla L, Mastella G. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: a cross-over randomized study. Pediatr Pulmonol. 1995;19(1):16-22.
    • (1995) Pediatr Pulmonol , vol.19 , Issue.1 , pp. 16-22
    • Braggion, C.1    Cappelletti, L.M.2    Cornacchia, M.3    Zanolla, L.4    Mastella, G.5
  • 85
    • 34548048797 scopus 로고    scopus 로고
    • Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    • Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007;132(2): 562-568.
    • (2007) Chest , vol.132 , Issue.2 , pp. 562-568
    • Merlo, C.A.1    Boyle, M.P.2    Diener-West, M.3    Marshall, B.C.4    Goss, C.H.5    Lechtzin, N.6
  • 86
    • 33644508050 scopus 로고    scopus 로고
    • Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa
    • Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006;73(1):27-33.
    • (2006) Respiration , vol.73 , Issue.1 , pp. 27-33
    • Lechtzin, N.1    John, M.2    Irizarry, R.3    Merlo, C.4    Diette, G.B.5    Boyle, M.P.6
  • 87
    • 33745910567 scopus 로고    scopus 로고
    • The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: A review of the recent literature
    • Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res. 2006;4(2):138-146.
    • (2006) Clin Med Res , vol.4 , Issue.2 , pp. 138-146
    • Falagas, M.E.1    Kasiakou, S.K.2    Tsiodras, S.3    Michalopoulos, A.4
  • 88
    • 0002088906 scopus 로고
    • The properties and mode of action of the polymyxins
    • Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev. 1956;20(1):14-27.
    • (1956) Bacteriol Rev , vol.20 , Issue.1 , pp. 14-27
    • Newton, B.A.1
  • 89
    • 0035171243 scopus 로고    scopus 로고
    • Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines
    • Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001;39(1):183-190.
    • (2001) J Clin Microbiol , vol.39 , Issue.1 , pp. 183-190
    • Gales, A.C.1    Reis, A.O.2    Jones, R.N.3
  • 90
    • 0035118424 scopus 로고    scopus 로고
    • In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
    • Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45(3):781-785.
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.3 , pp. 781-785
    • Li, J.1    Turnidge, J.2    Milne, R.3    Nation, R.L.4    Coulthard, K.5
  • 91
    • 17644389620 scopus 로고    scopus 로고
    • Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
    • Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333-1341.
    • (2005) Clin Infect Dis , vol.40 , Issue.9 , pp. 1333-1341
    • Falagas, M.E.1    Kasiakou, S.K.2
  • 92
    • 34447560960 scopus 로고    scopus 로고
    • Toxicity of polymyxins: A systematic review of the evidence from old and recent studies
    • Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.
    • (2006) Crit Care , vol.10 , Issue.1
    • Falagas, M.E.1    Kasiakou, S.K.2
  • 93
    • 77955627319 scopus 로고    scopus 로고
    • Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management
    • Parkins MD, Elborn JS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother. 2010;65(9):1853-1861.
    • (2010) J Antimicrob Chemother , vol.65 , Issue.9 , pp. 1853-1861
    • Parkins, M.D.1    Elborn, J.S.2
  • 94
    • 67749135403 scopus 로고    scopus 로고
    • In vitro activity of doripenem
    • Sahm D. In vitro activity of doripenem. Clin Infect Dis. 2009; 49 Suppl 1:S11-S16
    • (2009) Clin Infect Dis , vol.49 , Issue.SUPPL. 1
    • Sahm, D.1
  • 95
    • 34248334196 scopus 로고    scopus 로고
    • Comparative review of the carbapenems
    • Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-1052.
    • (2007) Drugs , vol.67 , Issue.7 , pp. 1027-1052
    • Zhanel, G.G.1    Wiebe, R.2    Dilay, L.3
  • 96
    • 67650470947 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers
    • Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol. 2009;49(7):798-806.
    • (2009) J Clin Pharmacol , vol.49 , Issue.7 , pp. 798-806
    • Cirillo, I.1    Vaccaro, N.2    Turner, K.3    Solanki, B.4    Natarajan, J.5    Redman, R.6
  • 97
    • 41649099025 scopus 로고    scopus 로고
    • Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study
    • Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36(4):1089-1096.
    • (2008) Crit Care Med , vol.36 , Issue.4 , pp. 1089-1096
    • Chastre, J.1    Wunderink, R.2    Prokocimer, P.3    Lee, M.4    Kaniga, K.5    Friedland, I.6
  • 98
    • 45749156804 scopus 로고    scopus 로고
    • In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU study
    • Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU study. J Antimicrob Chemother. 2008;62(1):206-208.
    • (2008) J Antimicrob Chemother , vol.62 , Issue.1 , pp. 206-208
    • Walkty, A.1    Decorby, M.2    Nichol, K.3    Karlowsky, J.A.4    Hoban, D.J.5    Zhanel, G.G.6
  • 99
    • 44949113364 scopus 로고    scopus 로고
    • Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
    • CD006961
    • Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008;3:CD006961.
    • (2008) Cochrane Database Syst Rev , vol.3
    • Waters, V.1    Ratjen, F.2
  • 100
    • 34548833833 scopus 로고    scopus 로고
    • Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms
    • Aaron SD. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev. 2007;8(3):256-261.
    • (2007) Paediatr Respir Rev , vol.8 , Issue.3 , pp. 256-261
    • Aaron, S.D.1
  • 101
    • 0034820682 scopus 로고    scopus 로고
    • Pseudomonas vaccination and immunotherapy: An overview
    • Holder IA. Pseudomonas vaccination and immunotherapy: an overview. J Burn Care Rehabil. 2001;22(5):311-320.
    • (2001) J Burn Care Rehabil , vol.22 , Issue.5 , pp. 311-320
    • Holder, I.A.1
  • 102
    • 3042638668 scopus 로고    scopus 로고
    • Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection
    • Lang AB, Rüdeberg A, Schöni MH, Que JU, Fürer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J. 2004;23(6):504-510.
    • (2004) Pediatr Infect Dis J , vol.23 , Issue.6 , pp. 504-510
    • Lang, A.B.1    Rüdeberg, A.2    Schöni, M.H.3    Que, J.U.4    Fürer, E.5    Schaad, U.B.6
  • 103
    • 55049131107 scopus 로고    scopus 로고
    • Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis
    • CD001399
    • Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 2008;4:CD001399.
    • (2008) Cochrane Database Syst Rev , vol.4
    • Johansen, H.K.1    Gøtzsche, P.C.2
  • 104
    • 0024805809 scopus 로고
    • Biological role of different antibody classes
    • Spiegelberg HL. Biological role of different antibody classes. Int Arch Allergy Appl Immunol. 1989;90 Suppl 1:22-27.
    • (1989) Int Arch Allergy Appl Immunol , vol.90 , Issue.SUPPL. 1 , pp. 22-27
    • Spiegelberg, H.L.1
  • 105
    • 67749124368 scopus 로고    scopus 로고
    • Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers
    • Lazar H, Horn MP, Zuercher AW, et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother. 2009;53(8):3442-3446.
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.8 , pp. 3442-3446
    • Lazar, H.1    Horn, M.P.2    Zuercher, A.W.3
  • 107
    • 34250169414 scopus 로고    scopus 로고
    • Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model
    • McVay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother. 2007;51(6):1934-1938.
    • (2007) Antimicrob Agents Chemother , vol.51 , Issue.6 , pp. 1934-1938
    • McVay, C.S.1    Velásquez, M.2    Fralick, J.A.3
  • 108
    • 33846612678 scopus 로고    scopus 로고
    • Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice
    • Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51(2): 446-452.
    • (2007) Antimicrob Agents Chemother , vol.51 , Issue.2 , pp. 446-452
    • Watanabe, R.1    Matsumoto, T.2    Sano, G.3
  • 109
    • 68349154135 scopus 로고    scopus 로고
    • A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy
    • Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349-357.
    • (2009) Clin Otolaryngol , vol.34 , Issue.4 , pp. 349-357
    • Wright, A.1    Hawkins, C.H.2    Anggård, E.E.3    Harper, D.R.4
  • 110
    • 67650446165 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa virulence and therapy: Evolving translational strategies
    • Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med. 2009;37(5):1777-1786.
    • (2009) Crit Care Med , vol.37 , Issue.5 , pp. 1777-1786
    • Veesenmeyer, J.L.1    Hauser, A.R.2    Lisboa, T.3    Rello, J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.